Quarterly ResultMay 5, 2026, 04:15 PM
Arcus Biosciences Q1 Revenue $17M; Net Loss $128M; Discontinues STAR-121
AI Summary
Arcus Biosciences reported Q1 2026 revenues of $17 million, down from $28 million in Q1 2025, and a net loss of $128 million, compared to $112 million in the prior year. The company announced the discontinuation of the Phase 3 STAR-121 study for domvanalimab plus zimberelimab in NSCLC due to futility. Arcus is advancing casdatifan for ccRCC, with Phase 3 enrollment expected by year-end 2026, and is progressing its inflammation and immunology pipeline with AB102 entering the clinic in Q3 2026. The company maintains a cash runway until at least H2 2028.
Key Highlights
- Discontinued Phase 3 STAR-121 study for domvanalimab in NSCLC due to futility analysis.
- Q1 2026 revenues were $17 million, down from $28 million in Q1 2025.
- Q1 2026 net loss was $128 million, compared to $112 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $876 million as of March 31, 2026.
- Cash runway extended until at least the second half of 2028, with $600 million expected by year-end 2026.
- AB102, an MRGPRX2 antagonist, expected to enter clinic in Q3 2026.
- Enrollment for casdatifan's Phase 3 PEAK-1 study expected to complete by year-end 2026.
- Full year 2026 GAAP revenue guidance is $50 million to $65 million.